- Home
- III vs PVLA Comparison
III vs PVLA Comparison
Compare III & PVLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- III
- PVLA
- Stock Information
- Founded
- III 2006
- PVLA 2015
- Country
- III United States
- PVLA United States
- Employees
- III N/A
- PVLA N/A
- Industry
- III Professional Services
- PVLA Biotechnology: Pharmaceutical Preparations
- Sector
- III Consumer Discretionary
- PVLA Health Care
- Exchange
- III Nasdaq
- PVLA Nasdaq
- Market Cap
- III 249.2M
- PVLA 285.2M
- IPO Year
- III 2007
- PVLA N/A
- Fundamental
- Price
- III $5.24
- PVLA $56.84
- Analyst Decision
- III Buy
- PVLA Strong Buy
- Analyst Count
- III 1
- PVLA 12
- Target Price
- III $5.50
- PVLA $59.00
- AVG Volume (30 Days)
- III 180.9K
- PVLA 123.6K
- Earning Date
- III 11-06-2025
- PVLA 08-14-2025
- Dividend Yield
- III 3.44%
- PVLA N/A
- EPS Growth
- III N/A
- PVLA N/A
- EPS
- III 0.16
- PVLA N/A
- Revenue
- III $240,201,000.00
- PVLA N/A
- Revenue This Year
- III N/A
- PVLA N/A
- Revenue Next Year
- III $5.10
- PVLA N/A
- P/E Ratio
- III $33.39
- PVLA N/A
- Revenue Growth
- III N/A
- PVLA N/A
- 52 Week Low
- III $2.95
- PVLA $11.17
- 52 Week High
- III $5.30
- PVLA $61.48
- Technical
- Relative Strength Index (RSI)
- III 63.42
- PVLA 64.06
- Support Level
- III $5.10
- PVLA $49.81
- Resistance Level
- III $5.29
- PVLA $61.48
- Average True Range (ATR)
- III 0.13
- PVLA 4.43
- MACD
- III 0.00
- PVLA -0.19
- Stochastic Oscillator
- III 82.86
- PVLA 62.41
About III Information Services Group Inc.
Information Services Group Inc is a U.S.-based technology insight, market intelligence, and advisory services firm. It principally offers digital transformation services, such as automation and cloud & data analytics; managed governance; network carrier services; technology plan and operations design; changes management; market intelligence & technology research and analysis. It operates in one segment, fact-based sourcing advisory services. Its geographical segments are the Americas, Europe, and Asia-pacific, out of which maximum revenue is derived from Americas.
About PVLA Palvella Therapeutics Inc. Common Stock
Palvella Therapeutics Inc is a late clinical-stage biopharmaceutical company committed to serving individuals suffering from serious, rare genetic skin diseases without approved therapies. The Company's lead product candidate, QTORIN 3.9 percent rapamycin anhydrous gel (QTORIN rapamycin), is based on the Company's patented QTORIN platform. QTORIN rapamycin is in clinical development for two rare genetic skin disorders.